Extended Data Table 1 Treatment efficacy in patients with PD-L1-negative tumors

From: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

  1. CR: complete response; DoR: duration of response; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PR: partial response; TTR: time to treatment response
Back to article page